[
  {
    "ts": null,
    "headline": "Why IBD Stock Of The Day Harrow Has Its Sights On A Breakout",
    "summary": "Harrow is Monday's IBD Stock Of The Day. The biotech stock is setting up to tack a handle onto a seven-week cup.",
    "url": "https://finnhub.io/api/news?id=250e93eff2390e32ef3dea308f05f103b988ff25a8f0e6ced0797822937c1223",
    "source": "Yahoo",
    "provider": "finnhub",
    "raw": {
      "category": "company",
      "datetime": 1771874435,
      "headline": "Why IBD Stock Of The Day Harrow Has Its Sights On A Breakout",
      "id": 139187395,
      "image": "https://s.yimg.com/rz/stage/p/yahoo_finance_en-US_h_p_finance_2.png",
      "related": "REGN",
      "source": "Yahoo",
      "summary": "Harrow is Monday's IBD Stock Of The Day. The biotech stock is setting up to tack a handle onto a seven-week cup.",
      "url": "https://finnhub.io/api/news?id=250e93eff2390e32ef3dea308f05f103b988ff25a8f0e6ced0797822937c1223"
    }
  },
  {
    "ts": null,
    "headline": "PorTal Access, Inc. Appoints Industry Veteran David Snow to Board of Directors to Advance Next-Generation Oncology Vascular Access Solutions",
    "summary": "PorTal Access, Inc., a pioneering medical device startup developing advanced vascular access solutions for oncology, announced today that David Snow, a seasoned biotechnology and pharmaceutical executive, has joined its Board of Directors. Snow's appointment strengthens the company's leadership as it advances the development of its Flexi-Port™ SLF-TANL, a next-generation chemo-port designed to reduce complications and improve patient care in hospital, bedside and outpatient settings.",
    "url": "https://finnhub.io/api/news?id=e88725e2856fefa79876113b0acc1b1d383f21e4b0f28a80b7e90678362a2cc1",
    "source": "Yahoo",
    "provider": "finnhub",
    "raw": {
      "category": "company",
      "datetime": 1771869180,
      "headline": "PorTal Access, Inc. Appoints Industry Veteran David Snow to Board of Directors to Advance Next-Generation Oncology Vascular Access Solutions",
      "id": 139186558,
      "image": "https://s.yimg.com/rz/stage/p/yahoo_finance_en-US_h_p_finance_2.png",
      "related": "REGN",
      "source": "Yahoo",
      "summary": "PorTal Access, Inc., a pioneering medical device startup developing advanced vascular access solutions for oncology, announced today that David Snow, a seasoned biotechnology and pharmaceutical executive, has joined its Board of Directors. Snow's appointment strengthens the company's leadership as it advances the development of its Flexi-Port™ SLF-TANL, a next-generation chemo-port designed to reduce complications and improve patient care in hospital, bedside and outpatient settings.",
      "url": "https://finnhub.io/api/news?id=e88725e2856fefa79876113b0acc1b1d383f21e4b0f28a80b7e90678362a2cc1"
    }
  },
  {
    "ts": null,
    "headline": "Tessera Therapeutics Receives U.S. FDA Fast Track and Orphan Drug Designations for its Lead In Vivo Gene Editing Program TSRA-196 for the Treatment of Adults with AATD",
    "summary": "SOMERVILLE, Mass., Feb. 23, 2026 (GLOBE NEWSWIRE) -- Tessera Therapeutics, the biotechnology company pioneering a new approach in genetic medicine known as Gene Writing™, today announced that the U.S. Food and Drug Administration (FDA) has granted Fast Track and Orphan Drug designations to TSRA-196, its lead in vivo gene editing program. TSRA-196 is being jointly developed with Regeneron for the treatment of adults with alpha-1 antitrypsin deficiency (AATD) who are homozygous for the PiZ allele",
    "url": "https://finnhub.io/api/news?id=e13fbbe7f644614ff32054139511ff6b07f9c8d58ea8e1f20de08b34dd2a58ac",
    "source": "Yahoo",
    "provider": "finnhub",
    "raw": {
      "category": "company",
      "datetime": 1771848000,
      "headline": "Tessera Therapeutics Receives U.S. FDA Fast Track and Orphan Drug Designations for its Lead In Vivo Gene Editing Program TSRA-196 for the Treatment of Adults with AATD",
      "id": 139183806,
      "image": "https://s.yimg.com/rz/stage/p/yahoo_finance_en-US_h_p_finance_2.png",
      "related": "REGN",
      "source": "Yahoo",
      "summary": "SOMERVILLE, Mass., Feb. 23, 2026 (GLOBE NEWSWIRE) -- Tessera Therapeutics, the biotechnology company pioneering a new approach in genetic medicine known as Gene Writing™, today announced that the U.S. Food and Drug Administration (FDA) has granted Fast Track and Orphan Drug designations to TSRA-196, its lead in vivo gene editing program. TSRA-196 is being jointly developed with Regeneron for the treatment of adults with alpha-1 antitrypsin deficiency (AATD) who are homozygous for the PiZ allele",
      "url": "https://finnhub.io/api/news?id=e13fbbe7f644614ff32054139511ff6b07f9c8d58ea8e1f20de08b34dd2a58ac"
    }
  }
]